CoChat

A clonal expression biomarker associates with lung cancer mortality

Open access
TRACERx Consortium, Biswas, Dhruva, Birkbak, Nicolai J., Rosenthal, Rachel, Hiley, Crispin T., Lim, Emilia L., Papp, Krisztian, Boeing, Stefan, Krzystanek, Marcin, Djureinovic, Dijana, La Fleur, Linnea, Greco, Maria, Döme, Balázs, Fillinger, János, Brunnström, Hans, Wu, Yin, Moore, David A., Skrzypski, Marcin, Abbosh, Christopher, Litchfield, Kevin, Al Bakir, Maise, Watkins, Thomas B. K., Veeriah, Selvaraju, Wilson, Gareth A., Jamal-Hanjani, Mariam, Moldvay, Judit, Botling, Johan, Chinnaiyan, Arul M., Micke, Patrick, Hackshaw, Allan, Bartek, Jiri, Csabai, Istvan, Szallasi, Zoltan, Herrero, Javier, McGranahan, Nicholas, Swanton, Charles · 2019 · Nature Medicine
Cited by 127

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumor stage1. Transcriptomic intratumor heterogeneity (RNA-ITH) has been shown to confound existing expression-based biomarkers across multiple cancer types2–6. Here, we analyze multi-region whole-exome and RNA sequencing data for 156 tumor regions from 48 patients enrolled in the TRACERx study to explore and control for RNA-ITH in non-small cell lung cancer. We find that chromosomal instability is a major driver of RNA-ITH, and existing prognostic gene expression signatures are vulnerable to tumor sampling bias. To address this, we identify genes expressed homogeneously within individual tumors that encode expression modules of cancer cell proliferation and are often driven by DNA copy-number gains selected early in tumor evolution. Clonal transcriptomic biomarkers overcome tumor sampling bias, associate with survival independent of clinicopathological risk factors, and may provide a general strategy to refine biomarker design across cancer types. TRACERx Lung: Intratumoral transcriptional heterogeneity, which often hinders the development of clinically useful RNA-expression-biased biomarkers for cancer, can now be overcome with an approach for the identification of clonal expression biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0595-z

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 127

Metadata

Authors
TRACERx Consortium, Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., La Fleur, L., Greco, M., Döme, B., Fillinger, J., Brunnström, H., Wu, Y., Moore, D. A., Skrzypski, M., Abbosh, C., Litchfield, K., Al Bakir, M., Watkins, T. B. K., Veeriah, S., Wilson, G. A., Jamal-Hanjani, M., Moldvay, J., Botling, J., Chinnaiyan, A. M., Micke, P., Hackshaw, A., Bartek, J., Csabai, I., Szallasi, Z., Herrero, J., McGranahan, N., & Swanton, C.
Venue
Nature Medicine
Published
2019-10
Volume
25
Issue
10
Pages
1540-1548
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2978549968
Cited by
127
References
20
FWCI
3.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A clonal expression biomarker associates with lung cancer mortality. https://app.cochat.ai/papers/10.1038/s41591-019-0595-z
The paper
TRACERx Consortium, Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., La Fleur, L., Greco, M., Döme, B., Fillinger, J., Brunnström, H., Wu, Y., Moore, D. A., Skrzypski, M., Abbosh, C., . . . Swanton, C. (2019). A clonal expression biomarker associates with lung cancer mortality. Nature Medicine. https://doi.org/10.1038/s41591-019-0595-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.